Veracyte announces evidence supporting thyroid genomic test

By LabPulse.com staff writers

June 20, 2022 -- Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules.

When the test deems a nodule suspicious, the patient's risk of malignancy is consistent and higher than that reported in the classifier's original clinical validation study, the firm said.

In the new meta-analysis, researchers evaluated 13 independent studies and found that the Afirma GSC's ability to identify benign nodules with high sensitivity and high negative predictive value for thyroid cancer was similar to the original clinical validation study results (97% vs. 91% and 99% vs. 96%, respectively).

Additionally, the meta-analysis data showed that the Afirma test's performance surpasses that shown in the original study when predicting the risk of malignancy in nodules labeled suspicious (65% positive predictive value vs. 47%).

The findings were presented at the ENDO 2022 Annual Conference held from June 11 through June 14 in Atlanta.

Veracyte touts gene expression study data at ESMO meeting
Gene expression profile (GEP) testing helps guide treatment decisions for women with early-stage breast cancer, according to a presentation from Veracyte...
Veracyte to highlight new Decipher data at ASCO meeting
Veracyte plans to highlight data from six poster abstracts regarding its Decipher urologic cancer tests at the upcoming American Society of Clinical Oncology...
Veracyte touts results of Percepta genomic sequencing study
Veracyte has released data from a study that used the company's Percepta genomic sequencing classifier, which the company reported can deliver curative...
Veracyte touts results of Decipher classifier study
Veracyte shared data from a study touting the success of its Decipher Prostate Biopsy genomic classifier in helping guide treatment decisions for prostate...
Veracyte taps new executive vice president, CFO
Global genomic diagnostics firm Veracyte has appointed Rebecca Chambers as its new executive vice president and chief financial officer (CFO). Her tenure...

Copyright © 2022 LabPulse.com

Last Updated mp 6/20/2022 10:10:59 AM